Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: RORα inhibits gastric cancer proliferation through attenuating G6PD and PFKFB3 induced glycolytic activity

Fig. 1

RORα is associated with GC proliferation and glycolysis. A GSEA algorithm analysis according to Reactome and Wikipathways database, respectively. B The difference analysis of CTC number and VEGF levels in RORα-high and RORα-low groups. C Left: Representative 18F-FDG PET/CT images of GC patients with maximum and minimum SUVmax levels. Up: The correlation analysis of SUVmax levels with CTC number and VEGF levels in GC patients, respectively. Down: The difference analysis of SUVmax levels in RORα-high and RORα-low groups. D G6PD and PFKFB3 mRNA expression levels in stomach adenocarcinoma-tumor (STAD-tumor) tissues and stomach adenocarcinoma-normal (STAD-normal) tissues from TCGA database were analyzed through TIMER 2.0. F Up: RORα, G6PD and PFKFB3 expression levels were detected through immunohistochemistry stain in normal gastric and GC patients with pT2N+, pT3N+ and pT4N+ stages tissues. Original 200 and 400 magnification. Scale bar =100 μm. Down: The correlation analysis of RORα expression levels with G6PD and PFKFB3 expression levels in GC patients, respectively. G The DFS time of GC patients with different RORα, G6PD and PFKFB3 expression patterns. All data are represented as the mean ± standard deviation. *P < 0.05, **P < 0.01, and ***P < 0.001

Back to article page